Tumor-Draining Lymph Node-Targeted Electrochemotherapy: A Hypothesis for In Situ Cancer Vaccination

Area of Science:

• Oncology
• Immunology
• Nanotechnology

Background:

• Immune checkpoint inhibitors (ICIs) show promise in cancer immunotherapy but face limitations due to tumor microenvironment factors and T-cell dysfunction.
• Current clinical trials suggest no significant survival benefit of sentinel lymph node biopsy (SLNB) over no lymph node surgery in early-stage cancers.
• Novel combinatorial strategies are needed to enhance treatment efficacy and overcome resistance in solid tumors.

Purpose of the Study:

• To explore the potential of tumor-draining lymph node (TDLN)-targeted electrochemotherapy (ECT) as a novel cancer immunotherapy approach.
• To investigate TDLN-targeted ECT as an in situ cancer vaccination strategy to enhance systemic anti-tumor immunity.
• To evaluate the feasibility of TDLN-targeted ECT in preserving lymph node function while eradicating tumor cells.

Main Methods:

• Tumor electrochemotherapy (ECT) utilizing high electric fields to enhance chemotherapeutic drug uptake and induce immunogenic cell death (ICD).
• Application of ECT targeted to tumor-draining lymph nodes (TDLNs) to stimulate immune responses within the lymph nodes.
• Assessment of DAMPs release, ICD induction, and subsequent immune cell activation within TDLNs.

Main Results:

• ECT induces immunogenic cell death (ICD) and releases damage-associated molecular patterns (DAMPs), overcoming immunosuppressive tumor microenvironments.
• TDLN-targeted ECT has the potential to act as an in situ cancer vaccination, activating immune cells within TDLNs.
• This approach may preserve lymph node integrity and lymphatic drainage while eradicating micrometastatic disease.

Conclusions:

• TDLN-targeted ECT represents a promising strategy to enhance systemic anti-tumor immunity by leveraging the immunostimulatory potential of lymph nodes.
• This approach could improve outcomes for patients with early-stage cancers, particularly those with negative lymph node assessments.
• Neoadjuvant TDLN-targeted ECT may enhance immune memory and reduce the risk of immune evasion post-surgery.